Minimal Hepatic Encephalopathy: a Vehicle for Accidents and Traffic Violations
Overview
Affiliations
Objectives: MHE patients have impairment on driving tests. However, it is unclear whether this impairment is restricted to the testing environment or is associated with increased traffic violations and/or motor vehicle accidents.
Methods: An anonymous driving history and driving behavior questionnaire (DBQ: self-scored, best score 104), coded according to MHE status, was sent to 200 cirrhotics without overt hepatic encephalopathy and 100 age/education-matched controls. The questionnaire inquired about demographics, alcohol/illegal drug use, and violations/accidents within 1 and 5 yr. The cirrhotics had been divided into those with MHE (MHE+), without MHE (MHE-), and those not tested for MHE because of psychoactive drug use, on a previous study.
Results: Cirrhotics versus controls had similar driving duration, alcohol/illegal drug use but significantly higher percentage with violations within both 1 and 5 yr (25%vs 4%[5 yr]), 13%vs 2%[(1 yr]), accidents (17%vs 4%[5 yr]), 9%vs 1%[1 yr]), and both (34%vs 7%[5 yr], 18%vs 3%[1 yr]). MHE+ cirrhotics had significantly higher percentage with violations (36%[5 yr], 21%[1 yr]), accidents (33%[5 yr]), 17%[1 yr]), and both (53%[5 yr], 33%[1 yr]) versus other cirrhotics. DBQ score was significantly lower in cirrhotics than controls (92 vs 99). Within cirrhotics, DBQ score was highest in MHE-versus other groups. MHE+ status was the only risk factor (odds ratios: 4.2-7.6) for violations and for accidents on multivariate logistic regression.
Conclusions: Cirrhotics have a higher self-reported occurrence of violations and accidents compared to controls. MHE+ a is strong predictor for violations and accidents. Prospective studies investigating the effect of MHE treatment on violations and accidents are warranted.
Ufere N, Lago-Hernandez C, Alejandro-Soto A, Walker T, Li L, Schoener K Hepatol Commun. 2024; 8(1).
PMID: 38206200 PMC: 10786597. DOI: 10.1097/HC9.0000000000000358.
Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?.
Faccioli J, Nardelli S, Gioia S, Riggio O, Ridola L J Clin Med. 2023; 12(12).
PMID: 37373598 PMC: 10298885. DOI: 10.3390/jcm12123903.
The Prevalence of Minimal Hepatic Encephalopathy in an Outpatient Hepatology Clinic.
Eyice D, Ok A, Sonsuz A, Senocak M, Durak M, Ozdemir S Turk J Gastroenterol. 2023; 34(5):560-567.
PMID: 36939610 PMC: 10334691. DOI: 10.5152/tjg.2023.21881.
Thanapirom K, Wongwandee M, Suksawatamnuay S, Thaimai P, Siripon N, Makhasen W J Clin Med. 2023; 12(2).
PMID: 36675448 PMC: 9864758. DOI: 10.3390/jcm12020519.
Faccioli J, Nardelli S, Gioia S, Riggio O, Ridola L J Clin Med. 2022; 11(23).
PMID: 36498820 PMC: 9736966. DOI: 10.3390/jcm11237246.